The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth

Gene

Volumn 277, Issue 1-2, 2001, Pages 15-30

  Cadwell, Craig ^a   Zambetti, Gerard P ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Apoptosis and tumorigenicity; Gain of function; Transactivation

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ANGIOGENESIS; APOPTOSIS; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTHERAPY; DNA DAMAGE; GENE MUTATION; GROWTH REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; RADIATION; REVIEW; STRESS; TRANSACTIVATION; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; ANIMALS; CELL DIVISION; GENE EXPRESSION REGULATION; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUTATION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0035904394     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1119(01)00696-5     Document Type: Review

References (155)

1. Restoration of the transcription activation function to mutant p53 in human cancer cells
2. Wild-type and mutant forms of p53 activate human topoisomerase I: A possible mechanism for gain of function in mutants
3. p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53
4. Regulation of p53 function and stability by phosphorylation
5. mdm2 expression is induced by wild-type p53 activity
6. The Max network gone Mad
7. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
8. Cancer phenotype correlates with constitutional TP53 genotype in families with Li-Fraumeni syndrome
9. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
10. T cells from bax transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53
11. The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants
12. Regulators and mediators of the p53 tumor suppressor
13. Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage
14. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage
15. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage
16. Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53
17. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells
18. Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle
19. p53 mutants without a functional tetramerization domain are not oncogenic
20. Modulation of activity of the promoter of the human MDR1 gene by ras and p53
21. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
22. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers
23. Wild-type human p53 activates the human epidermal growth factor promoter
24. Mice lacking p21CIP/WAF1 undergo normal development, but are defective in G1 checkpoint control
25. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells
26. Gain of function mutations in p53
27. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
28. Definition of a consensus binding site for p53
29. Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family
30. The mdm2 oncogene can overcome wild-type p53 suppression of transformed cell growth
31. The p53 proto-oncogene can act as a suppressor of transformation
32. Pharmacological rescue of mutant p53 conformation and function
33. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain
34. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6
35. The p53 protein is an unusually shaped tetramer that binds directly to DNA
36. MBP1: A novel mutant p53-specific protein partner with oncogenic properties
37. The complexity of p53 modulation: Emerging patterns from divergent signals
38. Activation of sequence-specific binding by acetylation of the p53 C-terminal domain
39. 24, a p53 response gene involved in growth suppression and apoptosis
40. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control
41. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability
42. A mutant p53 transgene accelerates tumor development in heterozygous but not nullizygous p53-deficient mice
43. DNA damage-induced activation of p53 by the checkpoint kinase Chk2
44. Genomic instability in Gadd45a-deficient mice
45. Database of p53 gene somatic mutations in human tumors and cell lines
46. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
47. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness
48. Regulation of the specific DNA binding function of p53
49. Activation of the cryptic DNA binding function of mutant forms of p53
50. Small peptides activate the latent sequence-specific DNA binding function of p53
51. Two cellular proteins that bind to wild-type but not mutant p53
52. Tumor spectrum analysis in p53-mutant mice
53. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis
54. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
55. ATM associates with and phosphorylates p53: Mapping the region of interaction
56. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage
57. Bax-deficient mice with lymphoid hyperplasia and male germ cell death
58. p53: Puzzle and paradigm
59. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins
60. Regulation of p53 by hypoxia: Dissociation of transcriptional repression and apoptosis from p53-dependent transactivation
61. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP
62. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain
63. T antigen is bound to a host protein in SV40-transformed cells
64. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain
65. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene
66. p53, the cellular gatekeeper for growth and division
67. Complementation by wild-type p53 of interleukin-6 effects on M1 cells: Induction of cell cycle exit and cooperativity with c-myc suppression
68. Mutant p53 protein expression interferes with p53-independent apoptotic pathways
69. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants
70. Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
71. High metastatic potential in mice inheriting a targeted missense mutation
72. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage
73. Apoptotic and growth-promoting activity of E2F modulated by MDM2
74. Cancer therapy and p53
75. p53 status and the efficacy of cancer therapy in vivo
76. II31 protein is a transcriptional coactivator of the p53 protein
77. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function
78. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis
79. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
80. Post-translational modification of p53
81. Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene
82. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
83. Wild-type murine p53 represses transcription from the murine c-myc promoter in a human glial cell line
84. Mdm2: "big brother" of p53
85. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
86. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
87. Identification of an additional negative regulatory region for p53 sequence-specific DNA binding
88. Protein interactions at the carboxyl terminus of p53 result in induction of its in vitro transactivation potential
89. A gain of function p53 mutant promotes both genetic instability and cell survival in a novel p53-null mammary epithelial cell model
90. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a
91. Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-strand breaks
92. PUMA, a novel proapoptotic gene, is induced by p53
93. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis
94. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression
95. Stabilization of the MDM2 oncoprotein by mutant p53
96. p53 increases experimental metastatic capacity of murine carcinoma cells
97. Tumor-derived p53 mutant C174Y is a gain-of function mutant which activates the fos promoter and enhances colony formation
98. Signaling to p53: Breaking the MDM2-p53 circuit
99. The p53 pathway
100. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
101. Base transitions are the most frequent genetic changes at P53 in gastric cancer
102. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein
103. Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint
104. DNA damage activates p53 through a phosphorylation-acetylation cascade
105. The polyproline region of p53 is required to activate apoptosis but not growth arrest
106. The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region
107. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain
108. Reactivation of mutant p53: A new strategy for cancer therapy
109. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain
110. Wild-type p53 binds to the TATA-binding protein and represses transcription
111. Alterations in tumor development in vivo mediated by expression of wild-type or mutant p53 proteins
112. Regulation of specific DNA binding by p53: Evidence for a role for O-glycosylation and charged residues at the carboxy terminus
113. Relief of p53-mediated transcriptional repression by the adenovirus E1B19-kDa protein or the cellular Bcl-2 protein
114. Tumor surveillance via the ARF-p53 pathway
115. The ARF/p53 pathway
116. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
117. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization
118. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-induced sites
119. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen
120. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
121. Dominant negative effect of a germ-line mutant p53: A step fostering tumorigenesis
122. How phosphorylation regulates the activity of p53
123. ARF, participates in a regulatory feedback loop with p53 and MDM2
124. p53-independent role of MDM2 in TGF-B1 resistance
125. Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma
126. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2
127. II60
128. A role for ATR in the DNA damage-induced phosphorylation of p53
129. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2
130. Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation
131. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression
132. Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression
133. Identification of a novel p53 functional domain that is necessary for efficient growth suppression
134. Clinical implications of p53 mutations
135. p53 domains: Structure, oligomerization, and transformation
136. p53 domains: Identification and characterization of two autonomous DNA-binding regions
137. Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis
138. 172H mutant and p53-knockout mice after chemical carcinogenesis: Evidence for a gain of function
139. GADD45 induction of a G2/M cell cycle checkpoint
140. Nucleolar Arf sequesters Mdm2 and activates p53
141. ARF tumor suppressor
142. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene
143. DNA-binding activity of wild-type p53 protein is mediated by the central part of the molecule and controlled by its C terminus
144. Hot-spot mutants of p53 core domain evince characteristic local structural changes
145. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
146. Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids
147. The p53-mdm2 autoregulatory feedback loop
148. Characterization of tumor-associated Chk2 mutations
149. Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53
150. Interaction between the retinoblastoma protein and the oncoprotein MDM2
151. Cloning and characterization of the human BAG-1 gene promoter: Upregulation by tumor-derived p53 mutants
152. c-myc overexpression and p53 loss cooperate to promote genetic instability
153. PUMA Induces the rapid apoptosis of colorectal cancer cells
154. Association with Cdc2 and inhibition of Cdc2/Cylin B1 kinase activity by the p53-regulated protein Gadd45
155. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis